Kernalabs explores how mRNA technology enabled rapid vaccine development, with COVID-19 vaccines designed in months and granted emergency authorization within a year of the virus’s genetic sequence release. The breakthrough builds on six decades of research, demonstrating the potential for mRNA to revolutionize medicine beyond infectious diseases.
RNA biologist and industry executive Melissa Moore delivers a keynote at the **ASBMB 2025 Annual Meeting**, discussing RNA biology and therapeutics. As a former **Chief Scientific Officer at Moderna**, she contributed to mRNA-based medicine advancements. The talk highlights her expertise in shaping biotechnology’s future through scientific innovation.
Kerna Laboratories secures seed funding to advance its AI-driven biotech innovations. The San Francisco-based startup leverages artificial intelligence in life sciences research. Details on the funding amount remain undisclosed.
Kerna Laboratories launches an AI-driven platform to design and deliver next-generation mRNA therapeutics. The San Francisco-based startup targets key challenges in mRNA technology to expand its applications in genetic medicine. Founding leadership includes former executives from Deep Genomics and Moderna, backed by Gradient Ventures.
